Global strategies for the treatment of early-stage and advanced cervical cancerDueñas-González, Alfonsoa; Campbell, SergiobCurrent Opinion in Obstetrics and Gynecology: February 2016 - Volume 28 - Issue 1 - p 11–17 doi: 10.1097/GCO.0000000000000234 GYNECOLOGIC CANCER: Edited by Gottfried E. Konecny Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review Recent peer-reviewed publications on the treatment of early, locally advanced and advanced cervical cancer patients are reviewed to gain insight into the main research done in the field. Recent findings In early-stage patients where cure is offered to most patients, research focuses on more conservative or less morbid approaches to increase quality of life and reduce the treatment-related sexual dysfunction. No major advances have occurred for treating locally advanced disease since the introduction of concurrent chemoradiation, but efforts are directed to increase efficacy while reducing toxicity with the use of combination chemoradiation and modern radiation technologies. Molecular-targeted therapy and identification of targetable gene alterations as well as immunotherapy are actively pursued in patients with advanced disease. Summary Although global statistics indicate a trend for decreased age-standardized incidence rates, social and economical factors impede the uptake of therapeutic advances achieved as many patients have no access even to basic resources for treating cancer. The adherence to quality indicators in delivery of optimized standard concurrent chemoradiation and adherence to guidelines in cervical cancer surgery must not be underestimated. Major efforts are needed in both the scientific and social aspects of cervical cancer treatment to reduce mortality. aInstituto de Investigaciones Biomédicas UNAM/Instituto Nacional de Cancerología, Mexico City bUnidad de Medicina Familiar IMSS 53 Zapopan Jalisco, Zapopan, Mexico Correspondence to Alfonso Dueñas-Gonzalez, Instituto de Investigaciones Biomédicas UNAM/Instituto Nacional de Cancerología, San Fernando 22, Tlalpan 14080, Mexico City, Mexico. Tel: +52 55 54853034; e-mail: firstname.lastname@example.org Copyright © 2016 YEAR Wolters Kluwer Health, Inc. All rights reserved.